How to best pair immune checkpoint inhibitors with other agents known to have efficacy in genitourinary cancers was a key avenue of inquiry of many of the studies presented at the 2020 Genitourinary Cancers Symposium. Investigators presented findings from trials of immunotherapy in combination with PARP and tyrosine kinase inhibitors, antiandrogens, and other interventions.
Molecular characteristics of disease and mechanisms of resistance were other important topics at the interdisciplinary meeting, which featured more than 800 abstracts. Key opinion leaders spoke with OncologyLive®
to share their insights on the most exciting and pivotal updates in genitourinary cancer. Interviews live from the 2020 Genitourinary Cancers Symposium can be viewed on the OncLive®
News Network at onclive.com/link/7518
Mary-Ellen Taplin, MDDana-Farber Cancer Institute
Mary-Ellen Taplin, MD
... to read the full story